Immuneering Co. (NASDAQ:IMRX) Short Interest Update

Immuneering Co. (NASDAQ:IMRX) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,290,000 shares, an increase of 41.4% from the November 30th total of 1,620,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 10.2% of the company’s shares are sold short.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IMRX shares. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Immuneering in a research report on Thursday, November 14th. Morgan Stanley downgraded shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Finally, Chardan Capital restated a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.80.

Immuneering Stock Performance

NASDAQ:IMRX traded down $0.08 during mid-day trading on Monday, hitting $2.25. 320,437 shares of the company’s stock traded hands, compared to its average volume of 2,079,917. Immuneering has a twelve month low of $1.00 and a twelve month high of $7.68. The company has a market capitalization of $69.86 million, a P/E ratio of -1.14 and a beta of -0.33. The company has a fifty day moving average of $2.01 and a 200 day moving average of $1.73.

Institutional Trading of Immuneering

Several large investors have recently bought and sold shares of IMRX. Vontobel Holding Ltd. acquired a new position in Immuneering in the 3rd quarter worth approximately $25,000. Corsair Capital Management L.P. acquired a new stake in shares of Immuneering in the third quarter worth $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering during the second quarter worth $44,000. XTX Topco Ltd raised its holdings in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Immuneering during the second quarter valued at $67,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.